<prompt> FDA indications of inhaled NO isMalignant hypeensionPulmonary hypeension in newbornCyanotic CHDNone of the above  <response>: Inhaled nitric oxide has been approved by FDA for use in newborns with persistent pulmonary hypeension and has become the first line therapy for this disease. In this disease state, NO inhalation has been shown to reduce, significantly, the necessity for extracorporeal oxygenation.Refer: Morgan and Mikhails Clinical Anaesthesiology, 5th edition, pg no. 257 